ISTI LOGO
Towards a new dawn
×

img Acces sibility Controls

Research Projects Banner

Research Projects

Combating the Undruggable Ternary EGFR L858R-T790M-C797S Mutation Associated with Osimertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Implementing Organization

R.C. Patel College of Pharmacy, Shirpur
Principal Investigator
Dr. Harun M. Patel
Associate Professor
|
R.C. Patel College of Pharmacy, Shirpur

About

The US FDA approved Osimertinib (AZD9291) for treating metastatic EGFR-T790M NSCLC. However, a significant number of patients developed a C797S mutation, rendering Osimertinib resistant. This suggests a need for drugs to overcome this resistance obstacle. The current proposal focuses on designing and synthesizing fourth-generation triple mutant selective EGFR-L858R-T790M-C797S tyrosine kinase inhibitors to overcome this resistance in NSCLC chemotherapy.

Related Research

View All
Funding Organization
Funding Organization
Department of Science and Technology (DST)
Quick Information
Area of Research
Life Sciences & Biotechnology
Focus Area
Pharmaceutical chemistry
Start Year
2023
End Year
2025
Sanction Amount
₹ 44.61 L
Status
Completed
Output
No. of Research Paper
00
Technologies (If Any)
00
No. of PhD Produced
N/A
Startup (If Any)
00
No. of Patents
Filed :00
Grant :00
arrowtop